IntelGenx Pitch Deck Teardown: Leveraging Oral Thin Film

IntelGenx: Reimagining Drug Delivery Through Thin Film Technology

The IntelGenx investor presentation, dated November 2015, serves as a comprehensive overview of a publicly traded pharmaceutical company (TSX-V: IGX) transitioning from R&D to significant commercial execution. The deck focuses heavily on the technical superiority of their delivery platforms and the massive market opportunities they unlock by 'making approved drugs better.'

Slide 1: Title and Positioning

The cover slide establishes IntelGenx Corp. as a provider of 'Innovative Drug Delivery Solutions.' The tagline 'We Make Approved Drugs Better' is a critical strategic positioning statement. It suggests a lower-risk profile than traditional drug discovery; rather than finding new molecules, they improve the delivery of already-vetted substances. The slide includes the date (November 24, 2015) and their ticker symbols for the TSX-V and OTCQX markets.

Slide 2: The Listerine Connection

Slide 2 uses a highly recognizable consumer product—Listerine PocketPaks—to explain their core technology. By stating that the IntelGenx CEO was a co-developer of the Listerine breath strips, the company bridges the gap between a familiar consumer item and complex pharmaceutical applications. The slide lists the benefits of Oral Thin Films (OTF): ideal for elderly and pediatric patients, ease of swallowing, and quicker symptom relief. This slide serves as the 'Problem/Solution' anchor for the deck.

Slide 4: Investment Highlights and TAM

This slide summarizes the value proposition. It claims a total addressable market (TAM) of $19B. It breaks this down into two proprietary technologies: VersaFilm ($17B TAM) and VersaTab ($1.7B TAM). Key achievements listed include the first European marketing approval for RIZAPORT (migraines) and record Q3 revenue and profitability. This slide is designed to show both massive potential and current momentum.

Slide 6: VersaFilm Deep Dive

Focusing on their flagship technology, Slide 6 details the benefits of VersaFilm, including rapid disintegration without water and potential for reduced adverse effects. The slide segments the $17B market into four specific high-value targets: Opioid Dependence (Targeted Suboxone Sales: $1.7B), Schizophrenia ($5.2B), Migraine ($2B), and Erectile Dysfunction ($4.2B). This level of specificity helps investors understand exactly where the revenue will come from.

Slide 8: The Product Pipeline

The pipeline slide is a standard but essential component of any biotech or pharma deck. It tracks multiple indications from formulation development through to launch. Notably, it shows that their Major Depressive Disorder product (Forfivo XL) is already at the launch stage with Edgemont Pharmaceuticals. It also identifies Par Pharmaceuticals as a partner for Opioid Dependence. Several other indications, such as Migraine and Erectile Dysfunction, are shown as having 'Partnering Availability,' signaling a call to action for potential collaborators or a justification for future capital needs.

Slide 10: In-House Manufacturing

IntelGenx highlights its 'Full Manufacturing Capabilities' as a strategic asset. The slide outlines a three-step process: Blending, Coating, and Packaging. The stated goals are to increase profitability, reduce dependence on external partners, and provide a 'one-stop shop' for clients. For investors, this represents a vertical integration play that protects IP and improves margins compared to companies that outsource production.

Slide 12: Financial Performance

This slide provides visual proof of the company's growth. A bar chart compares Q3 2015 revenue ($2.38M) to Q3 2014 ($0.45M). It also shows the nine-month totals, with 2015 reaching $3.59M compared to $0.83M in 2014. The rapid growth trajectory is intended to validate the commercial viability of their technology and the effectiveness of their partnership strategy.

Slide 14: Leadership and Expertise

The 'Visionary, Experience Leadership' slide emphasizes technical depth. The team has '100+ years of combined industry experience.' Dr. Horst G. Zerbe’s profile reiterates his role in the Listerine strips and his 40+ patents. The presence of a CFO with biotech experience and a Director of R&D who co-invented their proprietary technology rounds out the executive tier. The footer notes that the company has 18 employees, 8 of whom hold Ph.D.s, reinforcing the image of a high-talent, R&D-heavy organization.

Slide 16: Conclusion

The deck concludes with a simple 'Thank You' slide and the company website. It lacks a formal 'Ask' or 'Use of Proceeds' slide, which is common for public company presentations intended for general investor relations rather than a specific private funding round.

What IntelGenx Does Well

The deck excels at establishing technical credibility . By linking their CEO to a household product like Listerine strips, they demystify their technology and prove it can be manufactured at scale. The use of specific TAM figures tied to well-known drugs (like Cialis and Suboxone) makes the market opportunity tangible rather than theoretical. Furthermore, the inclusion of a detailed pipeline chart provides a clear roadmap for future growth, showing that the company is not a 'one-trick pony' but a platform capable of addressing diverse medical needs.

What is Missing from the Deck

The most glaring omission is a detailed breakdown of unit economics . While they mention 'profitability' and 'increased margins' through in-house manufacturing, they do not provide specific data on production costs versus licensing fees or sales prices. Additionally, there is no competitor analysis slide. While they claim a 'limited number of competitors' on Slide 6, they do not name them or explain how VersaFilm specifically outperforms other OTF technologies in the market. Finally, as a public company presentation, it lacks a specific investment ask , which would be necessary for a private fundraising context.

What Other Founders Should Copy

Founders in the deep tech or life sciences space should emulate the way IntelGenx segments their TAM . Instead of just giving a large, vague number, they break it down by specific medical indications and even mention the 'targeted' brand-name drugs they are disrupting. This helps investors conduct their own due diligence on those specific sub-markets. The manufacturing slide is also a strong addition; it shows that the company has thought through the entire lifecycle of the product, from R&D to packaging, which reduces the perceived 'execution risk' for investors.